# 3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus

> **NCT02483624** · PHASE1 · TERMINATED · sponsor: **Northwell Health** · enrollment: 6 (actual)

## Conditions studied

- SLE

## Interventions

- **DRUG:** BR-DIM
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02483624
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2016-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02483624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02483624, "3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02483624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*